AU5270500A - Macromolecular carrier for drug and diagnostic agent delivery - Google Patents

Macromolecular carrier for drug and diagnostic agent delivery

Info

Publication number
AU5270500A
AU5270500A AU52705/00A AU5270500A AU5270500A AU 5270500 A AU5270500 A AU 5270500A AU 52705/00 A AU52705/00 A AU 52705/00A AU 5270500 A AU5270500 A AU 5270500A AU 5270500 A AU5270500 A AU 5270500A
Authority
AU
Australia
Prior art keywords
drug
diagnostic agent
agent delivery
macromolecular carrier
leashes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU52705/00A
Other languages
English (en)
Inventor
David R. Vera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
University of California Berkeley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, University of California Berkeley filed Critical University of California
Publication of AU5270500A publication Critical patent/AU5270500A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A61K49/128—Linear polymers, e.g. dextran, inulin, PEG comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
    • A61B6/508—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for non-human patients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dentistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
AU52705/00A 1999-05-14 2000-05-12 Macromolecular carrier for drug and diagnostic agent delivery Abandoned AU5270500A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13432999P 1999-05-14 1999-05-14
US60134329 1999-05-14
PCT/US2000/013300 WO2000069473A2 (en) 1999-05-14 2000-05-12 Macromolecular carrier for drug and diagnostic agent delivery

Publications (1)

Publication Number Publication Date
AU5270500A true AU5270500A (en) 2000-12-05

Family

ID=22462862

Family Applications (1)

Application Number Title Priority Date Filing Date
AU52705/00A Abandoned AU5270500A (en) 1999-05-14 2000-05-12 Macromolecular carrier for drug and diagnostic agent delivery

Country Status (10)

Country Link
US (1) US6409990B1 (https=)
EP (1) EP1178838B1 (https=)
JP (2) JP4056701B2 (https=)
AT (1) ATE277642T1 (https=)
AU (1) AU5270500A (https=)
DE (1) DE60014359T2 (https=)
ES (1) ES2228536T3 (https=)
FR (1) FR15C0033I2 (https=)
NL (1) NL300736I2 (https=)
WO (1) WO2000069473A2 (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770261B2 (en) * 1995-06-02 2004-08-03 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
EP1032430A2 (en) 1997-11-17 2000-09-06 Research Corporation Technologies, Inc. Magnetic resonance imaging agents for the detection of physiological agents
EP1178838B1 (en) * 1999-05-14 2004-09-29 The Regents of the University of California Macromolecular carrier based on dextran for drug and diagnostic agent delivery
US20040146463A1 (en) * 2000-05-04 2004-07-29 Meade Thomas J. Functional MRI agents for cancer imaging
US6673333B1 (en) * 2000-05-04 2004-01-06 Research Corporation Technologies, Inc. Functional MRI agents for cancer imaging
CN100406065C (zh) 2000-12-01 2008-07-30 细胞工厂治疗公司 糖基化/半乳糖基化肽、双官能接头和核苷酸单体/多聚体的缀合物以及相关的组合物和使用方法
US20030004236A1 (en) * 2001-04-20 2003-01-02 Meade Thomas J. Magnetic resonance imaging agents for detection and delivery of therapeutic agents and detection of physiological substances
WO2002087632A1 (en) * 2001-05-02 2002-11-07 Metaprobe, Inc. High throughput screening methods using magnetic resonance imaging agents
AU2002364607A1 (en) * 2001-12-28 2003-07-24 The Burnham Institute Novel ligand involved in the transmigration of leukocytes .
US20030198597A1 (en) * 2002-04-22 2003-10-23 Meade Thomas J. Novel macrocyclic activatible magnetic resonance imaging contrast agents
US7651689B2 (en) * 2002-11-15 2010-01-26 Albert Einstein College Of Medicine Of Yeshiva University Methods of applying ionization radiation for therapy of infections
EP1590440A4 (en) * 2003-02-03 2009-03-18 Palo Alto Inst Of Molecular Me CELL-KILLING MOLECULES AND METHODS FOR THEIR USE
US7727969B2 (en) * 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US20050171424A1 (en) * 2004-01-13 2005-08-04 The Gov. Of The Usa As Rep. By The Secretary Of The Dept. Of Health And Human Services Methods for imaging the lymphatic system using dendrimer-based contrast agents
US20050186642A1 (en) 2004-02-24 2005-08-25 Biocare Medical, Inc. Immunoassay reagents and methods of use thereof
US20070232904A1 (en) * 2004-06-03 2007-10-04 Oakley, Inc. Application of Hyaluronic Acid to Sentinel Lymph Node Identification
US7381400B2 (en) * 2004-07-13 2008-06-03 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Injection of a radioactive dye for sentinel lymph node identification
US20060204443A1 (en) * 2005-03-11 2006-09-14 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for tumor treatment using dendrimer conjugates
DE102005018330B4 (de) 2005-04-20 2007-04-19 Siemens Ag System zur Erzeugung von CT-Bilddatensätzen und zur Bestrahlung eines Tumor-Patienten
JP4934802B2 (ja) * 2005-05-30 2012-05-23 国立大学法人信州大学 リンパ系の細胞接着物質、リンパ系薬物輸送材およびそれを含有する薬剤
US20070031512A1 (en) * 2005-08-03 2007-02-08 Amcol International Corporation Virus-interacting layered phyllosilicates and methods of inactivating viruses
US20100272769A1 (en) * 2005-08-03 2010-10-28 Amcol International Virus-, Bacteria-, and Fungi-Interacting Layered Phyllosilicates and Methods of Use
US20080184618A1 (en) * 2005-08-03 2008-08-07 Amcol International Virus-Interacting Layered Phyllosilicates and Methods of Use
WO2008022263A2 (en) * 2006-08-17 2008-02-21 Epix Pharmaceuticals, Inc. Methods for lymph system imaging
US20100196272A1 (en) * 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
US11077212B2 (en) 2010-08-24 2021-08-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Molecular imaging of cancer cells in vivo
US8852592B2 (en) 2011-05-10 2014-10-07 Biocare Medical, Llc Systems and methods for anti-PAX8 antibodies
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
EP2900265B1 (en) 2012-09-27 2018-05-30 Biocare Medical, LLC Anti-uroplakin ii antibodies systems and methods
US10429390B2 (en) 2012-12-18 2019-10-01 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
DK2962113T3 (da) 2013-02-28 2019-07-01 Biocare Medical Llc Systemer og fremgangsmåder med anti-p40-antistoffer
JP6163698B2 (ja) * 2013-03-21 2017-07-19 国立大学法人 千葉大学 マクロファージマンノース受容体を認識する新規多糖金属錯体化合物、及び、その医薬組成物
CN114377143A (zh) * 2013-07-22 2022-04-22 康德乐健康414有限责任公司 用于诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒
CN104511030A (zh) * 2013-09-29 2015-04-15 复旦大学 基于葡聚糖的双模态纳米影像药物-Dex-Rho-99mTc
US9816997B2 (en) 2013-10-03 2017-11-14 Biocare Medical, Llc Anti-SOX10 antibody systems and methods
EP3154587B1 (en) 2014-06-13 2020-01-15 Tenboron OY Conjugates comprising an anti-egfr1 antibody
WO2016011419A1 (en) * 2014-07-17 2016-01-21 Ohio State Innovation Foundation Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis
CA2955438C (en) * 2014-07-17 2024-07-02 Ohio State Innovation Foundation DEXTRANE CONJUGATES TO TARGET MACROPHAGES AND OTHER CELLS EXPRESSING THE D-MANBOSE BINDING TYPE C LECTIN RECEPTOR
US10806803B2 (en) * 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis
WO2016118188A1 (en) * 2015-01-21 2016-07-28 Navidea Biopharmaceuticals, Inc. Compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells
CN106317237B (zh) * 2015-07-03 2019-07-19 华中科技大学 一种用于spect成像的当归多糖衍生物及其合成方法
CN108348619A (zh) 2015-09-25 2018-07-31 瑟日尼有限责任公司 Sn-117m标记的甘露糖偶联的葡聚糖胺
EP3359202A1 (en) 2015-10-05 2018-08-15 Serene, LLC Hyaluronan sn-117m colloid for radiosynoviorthersis and symptomatic therapy related applications
WO2018067751A1 (en) * 2016-10-04 2018-04-12 Navidea Biopharmaceuticals, Inc. Compositions and methods for diagnosing and treating macrophage-related disorders using carbohydrate-based macromolecular carrier
MX2019004029A (es) 2016-10-07 2019-09-27 Navidea Biopharmaceuticals Inc Compuestos y metodos para diagnosis y tratamiento de infecciones virales.
JP6329302B2 (ja) * 2017-05-10 2018-05-23 国立大学法人千葉大学 マクロファージマンノース受容体を認識する新規多糖金属錯体化合物、及び、その医薬組成物
US20210052639A1 (en) * 2019-08-19 2021-02-25 Navidea Biopharmaceuticals, Inc. Compositions and related methods for the ablation of m2 macrophages and myeloid derived suppressor cells
US20210145989A1 (en) * 2019-09-30 2021-05-20 Navidea Biopharmaceuticals, Inc. Compositions and related methods for blocking off-target localization of mannosylated dextrans and other cd206 ligands
US11497763B1 (en) 2020-07-01 2022-11-15 Physis International LLC Compounds and methods for treating and diagnosing RNA virus infections
US12070504B1 (en) 2020-07-01 2024-08-27 Physis International LLC Compounds and methods for altering cyto-states of cells that express c-type lectin receptors
EP4076540A4 (en) 2020-07-08 2024-02-21 Navidea Biopharmaceuticals, Inc. Synthesis of uniformly defined molecular weight mannosylated dextrans and derivatives thereof
CA3192041A1 (en) * 2020-08-21 2022-02-24 Resolute Science, Inc. Compositions and methods for targeting tumor-associated macrophages
EP4472643A1 (en) * 2022-02-04 2024-12-11 Navidea Biopharmaceuticals, Inc. Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking
US20230302041A1 (en) * 2022-03-25 2023-09-28 Navidea Biopharmaceuticals, Inc. Competitive Self-Blocking with Unlabeled Manocept Imaging Agents
WO2024076988A2 (en) * 2022-10-03 2024-04-11 Navidea Biopharmaceuticals, Inc. Amide linkages of sugar moieties to amine terminated leashes attached to carbohydrate polymers

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE286598C (https=)
US4707440A (en) * 1984-01-30 1987-11-17 Enzo Biochem, Inc. Nucleic acid hybridization assay and detectable molecules useful in such assay
US5175269A (en) * 1984-01-30 1992-12-29 Enzo Diagnostics, Inc. Compound and detectable molecules having an oligo- or polynucleotide with modifiable reactive group
SE465907B (sv) * 1984-11-01 1991-11-18 Nyegaard & Co As Diagnosticeringsmedel innehaallande en paramagnetisk metall
US5336762A (en) * 1985-11-18 1994-08-09 Access Pharmaceuticals, Inc. Polychelating agents for image and spectral enhancement (and spectral shift)
US5490991A (en) * 1986-07-03 1996-02-13 Advanced Magnetics, Inc. Directed delivery of radioprotectants using a receptor specific carrier
US4822594A (en) * 1987-01-27 1989-04-18 Gibby Wendell A Contrast enhancing agents for magnetic resonance images
CS263561B1 (en) * 1987-09-18 1989-04-14 Kery Vladimir Process for preparing water soluble allylderivatives of oligo and polysaccharides
DD286598A5 (de) * 1989-06-29 1991-01-31 Adw Der Ddr,Zi F. Mulekularbiologie,De Verfahren zur einfuehrung von primaeren aminogruppen in wasserloesliche polymere
US5789578A (en) * 1996-01-11 1998-08-04 Massey University Methods for the preparation of resins with ligands attached thereto through a linking group comprising sulfide, sulfoxide or sulfone functionality
ES2206689T3 (es) * 1996-10-28 2004-05-16 Amersham Health As Agentes de contraste.
WO1998023293A1 (en) * 1996-11-28 1998-06-04 Nihon Schering K.K. Contrast compound, contrast medium for mri, and method for mri
EP1178838B1 (en) * 1999-05-14 2004-09-29 The Regents of the University of California Macromolecular carrier based on dextran for drug and diagnostic agent delivery

Also Published As

Publication number Publication date
EP1178838A2 (en) 2002-02-13
NL300736I1 (https=) 2016-01-26
JP2007332380A (ja) 2007-12-27
EP1178838B1 (en) 2004-09-29
JP4056701B2 (ja) 2008-03-05
US6409990B1 (en) 2002-06-25
NL300736I2 (https=) 2016-01-26
DE60014359D1 (de) 2004-11-04
FR15C0033I2 (fr) 2016-09-09
WO2000069473A2 (en) 2000-11-23
ATE277642T1 (de) 2004-10-15
ES2228536T3 (es) 2005-04-16
DE60014359T2 (de) 2006-02-23
FR15C0033I1 (https=) 2015-06-26
WO2000069473A3 (en) 2001-08-16
JP2002544243A (ja) 2002-12-24

Similar Documents

Publication Publication Date Title
AU5270500A (en) Macromolecular carrier for drug and diagnostic agent delivery
ATE224888T1 (de) Pyridylalken- und pyridylalkin-säureamide als cytostatika und immunosuppressive arzneimittel
MY124695A (en) Novel composition and use.
TR199700213A2 (xx) 2-Aril s�bstit�entli piridinler.
AU6011701A (en) Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same
WO2001026693A3 (en) Manufacture of polyglutamate-therapeutic agent conjugates
DE69921138D1 (de) Arzneimittel freisetzendes system enthaltend ein homeobox-peptid und ein zytotoxisches oder antineoplastisches mittel
DE60038104D1 (de) Arzneimittelzubereitungen für die behandlung von alpha-galactosidase a-mangel
YU48701A (sh) Fenilfenantridini sa dejstvom inhibicije pde-iv
EP0466816A4 (en) Method for enhancing transmembrane transport of exogenous molecules
TR200102603T2 (tr) Antitümör aktiviteye sahip olan kamptotesin türevleri
TW261615B (https=)
TR200503846T2 (tr) Değiştirilmiş salimli ensülin sensitizörü için fterkip ve kullanımı
ES2080037T3 (es) Medicamento de uso topico con actividad cicatrizante.
NZ510154A (en) A tumour antigen protein and gene therefor, tumour antigen peptides and derivatives thereof in medicaments and prophylactics
AU7317400A (en) Transporter genes oatp-b, c, d and e
EP1466614A4 (de) Polypeptid, dessen konjugat doxorubicin enthält, und auf diesem basierende pharmazeutische zusammensetzung
WO2003094929A3 (en) Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
NZ506406A (en) Compositions comprising Mycobacterium phlei DNA and methods for its use in the treatment of bladder cancer
TR200302178T4 (tr) Ağrı ve alerjik reaksiyonlarla mücadele için sübstitüe edilmiş pirrol mannich bazları.
DK0742716T3 (da) Farmaceutisk sammensætning til systemisk transdermal indgivelse med det aktive middel morphin-6-glucuronid
BR9914031A (pt) Composições farmacêuticas micronizadas
DE60004826D1 (de) Dimere ruthenium komplexe für antimetastatische und antineoplastische arzneimittel
de Lafuente Cedars-Sinai chief exec announces resignation.
ITMI20020236A1 (it) Ossidazione ad attivita' antiproliferativa

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase